Chardan Capital reissued their buy rating on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT - Free Report) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $28.00 price objective on the stock.
A number of other analysts have also recently weighed in on EYPT. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of EyePoint Pharmaceuticals in a report on Friday. JPMorgan Chase & Co. dropped their price target on shares of EyePoint Pharmaceuticals from $32.00 to $29.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 13th. Scotiabank initiated coverage on EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $18.00 price objective for the company. Jefferies Financial Group began coverage on EyePoint Pharmaceuticals in a research report on Wednesday, August 28th. They issued a "buy" rating and a $15.00 target price on the stock. Finally, StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a research note on Saturday, September 21st. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.00.
Check Out Our Latest Report on EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Stock Down 4.8 %
EYPT stock traded down $0.58 during midday trading on Tuesday, reaching $11.54. The company had a trading volume of 1,685,120 shares, compared to its average volume of 928,525. The firm has a market capitalization of $617.62 million, a PE ratio of -6.45 and a beta of 1.57. The stock has a 50 day moving average price of $8.98 and a 200 day moving average price of $10.44. EyePoint Pharmaceuticals has a fifty-two week low of $5.67 and a fifty-two week high of $30.99.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.03). EyePoint Pharmaceuticals had a negative net margin of 172.29% and a negative return on equity of 43.24%. The company had revenue of $9.48 million for the quarter, compared to analyst estimates of $11.61 million. Research analysts predict that EyePoint Pharmaceuticals will post -2.33 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of EYPT. Greenwich Wealth Management LLC lifted its holdings in EyePoint Pharmaceuticals by 8.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company's stock valued at $93,000 after acquiring an additional 900 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of EyePoint Pharmaceuticals by 68.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company's stock worth $82,000 after purchasing an additional 4,172 shares in the last quarter. Cyndeo Wealth Partners LLC acquired a new stake in EyePoint Pharmaceuticals during the third quarter valued at approximately $100,000. Woodstock Corp boosted its holdings in EyePoint Pharmaceuticals by 29.1% during the third quarter. Woodstock Corp now owns 71,480 shares of the company's stock worth $571,000 after buying an additional 16,093 shares in the last quarter. Finally, Essex Investment Management Co. LLC grew its position in EyePoint Pharmaceuticals by 234.2% in the third quarter. Essex Investment Management Co. LLC now owns 142,144 shares of the company's stock worth $1,136,000 after buying an additional 99,606 shares during the last quarter. Institutional investors own 99.41% of the company's stock.
About EyePoint Pharmaceuticals
(
Get Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Further Reading
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
